Bandingkan kaedah

	Penilaian Global Doktor bagi Aktiviti Lupus (PGA)	Indeks Aktiviti Penyakit Spondilitis Ankilosis Mandi (BASDAI)	Indeks Aktiviti Penyakit Lupus Eritematosus Sistemik 2000 (SLEDAI-2K)
Bidang	Reumatologi	Reumatologi	Reumatologi
Keluarga	Process / pipeline	Process / pipeline	Process / pipeline
Tahun asal	1992	1994	2002
Pengasas	Bombardier et al.	Garrett et al.	Gladman et al.
Jenis	Clinician-rated	Patient-reported outcome (PRO)	Clinician-rated
Sumber perintis	Petri M. Thermodynamic instability in the pathogenesis of lupus nephritis. Nat Rev Rheum. 2016;12(11):635-642.	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
Alias	Physician Global Assessment, PGA-Lupus, Clinician Global Assessment-SLE	BASDAI, BAS-DAI	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
Berkaitan	3	4	3
Ringkasan	The Physician Global Assessment (PGA) is a clinician-rated, single-item measure of overall systemic lupus erythematosus (SLE) disease activity on a visual analogue scale (0–10). Used alongside structured indices like SLEDAI, PGA captures the clinician's integrated judgment of SLE severity, synthesising clinical examination, serology, imaging, and organ-specific findings into a holistic activity score. PGA is simple, practical, and widely used in SLE research and clinical practice as a complementary measure that reflects experienced clinician assessment of disease state.	The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.